Recent research into novel amylin analogs—such as cagrilintide, petrelintide, amycretin, and GUB014295—has focused on developing new treatments for diabetes and obesity, particularly in combination with GLP-1 receptor agonists. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.